The First Experience of Accelerator-based Lithium Neutron Capture Therapy in vivo
- 1Budker Institute of Nuclear Physics
Abstract
Boron neutron capture therapy (BNCT) is one of the promising treatment methods for cancer. BNCT is based on the unique high ability of the non-radioactive boron-10 (10B) nucleus to absorb thermal neutrons. The absorption of a neutron by boron results in a nuclear reaction 10B(n,)7Li with 84% of the energy being released within the cell, thereby inducing cancer cell death. We propose a novel approach based on using lithium instead of boron in neutron capture therapy: the neutron capture reaction cross-section for lithium is 4 times smaller than that of boron, while the energy release is 2 times higher, and the primary advantage of lithium is that 100% of the energy is released inside the cell. A series of in vivo neutron irradiation experiments using the murine B16 skin melanoma model demonstrated the efficacy of lithium neutron capture therapy (LiNCT). Higher lithium concentrations in the tumor achieved through intraperitoneal administration, compared to the oral route, contributed to a significant increase in animal survival and a significant decrease in tumor growth. The results of our study provide entirely new opportunities for the development of neutron capture therapy, both with lithium and with a possible lithium-boron combination.
Related
- Lipid–Metal-Organic Framework Colloidosomes for Multimodal Encapsulation and Pollutant Capture
- Carbon Capture and Utilization Through Microalgae and Carbonic Anhydrases: Opportunities, Challenges and Future Directions
- A Redox-Switchable Supramolecular Carbohydrate Chip for Capture and Real-Time Glycosylation Analysis of Living Suspension Cells
- 4D Spatio-temporal Capture of Leaf Morphogenesis Reveals Synchronisation between Growth and Motion
- Hoberman‐Inspired Reconfigurable DNA Origami Ring for Nanoscale Capture
BibTeX
@misc{taskaeva2026first,
title = {{The First Experience of Accelerator-based Lithium Neutron Capture Therapy in vivo}},
author = {I. Taskaeva and A. Kasatova and T. Bykov and V. Richter and E. Sokolova and N. Bgatova and S. Taskaev},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.04.749316},
url = {https://www.biorxiv.org/content/10.64898/2026.09.04.749316v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - The First Experience of Accelerator-based Lithium Neutron Capture Therapy in vivo
AU - I. Taskaeva
AU - A. Kasatova
AU - T. Bykov
AU - V. Richter
AU - E. Sokolova
AU - N. Bgatova
AU - S. Taskaev
PY - 2026
DA - 2026/09/04
PB - bioRxiv
DO - 10.64898/2026.09.04.749316
UR - https://www.biorxiv.org/content/10.64898/2026.09.04.749316v1
AB - Boron neutron capture therapy (BNCT) is one of the promising treatment methods for cancer. BNCT is based on the unique high ability of the non-radioactive boron-10 (10B) nucleus to absorb thermal neutrons. The absorption of a neutron by boron results in a nuclear reaction 10B(n,)7Li with 84% of the energy being released within the cell, thereby inducing cancer cell death. We propose a novel approach based on using lithium instead of boron in neutron capture therapy: the neutron capture reaction cross-section for lithium is 4 times smaller than that of boron, while the energy release is 2 times higher, and the primary advantage of lithium is that 100% of the energy is released inside the cell. A series of in vivo neutron irradiation experiments using the murine B16 skin melanoma model demonstrated the efficacy of lithium neutron capture therapy (LiNCT). Higher lithium concentrations in the tumor achieved through intraperitoneal administration, compared to the oral route, contributed to a significant increase in animal survival and a significant decrease in tumor growth. The results of our study provide entirely new opportunities for the development of neutron capture therapy, both with lithium and with a possible lithium-boron combination.
ER -